Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Parasitic merger? No thanks
View:
Post by Apostata on Feb 25, 2024 11:15pm

Parasitic merger? No thanks

No one -- not CZO, not AEZS, and not their unpaid online volunteer Proph -- has made a case for this being anything other than a parasitic merger, where the better outfit (CZO) is forced to have its advantages, its IP and its shareholder value sucked dry by a floundering mess of a company (AEZS). It's a political stinkball, with Gilles essentially giving up and going into full retirement-mode under the guise of a "merger of equals" , which is ludicrous given he's on the BoD of AEZS. 

Gilles has given up. We shouldn't. 

Vote NO and hopefully these clowns come to their senses and rid themselves of Gilles Gagnon.
Comment by prophetoffactz on Feb 26, 2024 4:46am
Apostata, "No one...has made a case for this being anything other than a parasitic merger, where the better outfit (CZO) is forced to have its advantages, its IP and its shareholder value sucked dry by a floundering mess of a company (AEZS)." You know more than Ronnie Miller and Dr. Li with Gilles by their side in the catbird of both companies along with Bloom Burton? The merger was ...more  
Comment by prophetoffactz on Feb 26, 2024 5:39am
AEZS could be bigger than CZO. It's nice to pick up that diversification in addition to the other advantages of the merger. AEZS's lead AIM Biologicals program targets a market expected to be worth US$2.5 billion. It is expected to have excellent tolerability. If safety is believed significantly addressed is it expected to work? It is based on natural science. In principle it works. The ...more  
Comment by Apostata on Feb 26, 2024 10:08am
Arguably the only people who want this parasitic merger are the more desperate shareholders of AEZS, who understand that if the merger is approved they get to increase their cash burn runway at CZO's expense.  This is a desperate, one-sided arrangement.  Vote NO. 
Comment by prophetoffactz on Feb 26, 2024 10:29am
This post has been removed in accordance with Community Policy
Comment by prophetoffactz on Feb 26, 2024 11:08am
Does a 'no' vote derail the access to capital the merger provides to accelerate CZO's plans for significant growth given the many opportunities in Friday's news release. Would it cause delays in CZO's plan? Would it also cause a new round of costs as CZO is forced to re-evaluate its strategic alternatives and potentially find a new merger partner over the next year and go ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities